PCM
APLS

Penserra Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Penserra Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,990
Closed -$65K – 1366
2021
Q3 		$65K Buy
1,990
+160
+9% +$8.99K ﹤0.01% 968
2021
Q2 		$115K Buy
1,830
+15
+0.8% +$774 ﹤0.01% 756
2021
Q1 		$77K Buy
1,815
+65
+4% +$3.08K ﹤0.01% 740
2020
Q4 		$100K Buy
1,750
+1,104
+171% +$46.7K ﹤0.01% 603
2020
Q3 		$19K Buy
+646
New +$19.3K ﹤0.01% 743

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Penserra Capital Management's APLS Position: Q4 2021 in Review

Penserra Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2021, closing a stake of 1,990 shares — an estimated $65K sold.

Penserra Capital Management first reported a position in APLS in Q3 2020 and held it in 5 quarters. The position peaked at $115K in Q2 2021. 186 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Penserra Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,990 Apellis Pharmaceuticals shares in Q4 2021, an estimated $65K.
  • Penserra Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Apellis Pharmaceuticals position peaked at $115K in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.